TissueCypher - Barrett's Esophagus

In case you missed it back in May, we wanted to reshare the highlights from our multi-specialist panel discussion featuring Dan Lister, MD FACS FAFS, Dr. Farhan Q., and Sarah Enslin, PA-C. You can watch the full-length session here: https://hubs.la/Q02G9zyF0 Highlights: 💬 Lister: "Before TissueCypher, the problem that we had was that an endoscopic biopsy provided a static picture of a dynamic situation... TissueCypher allows us to have a video so we know what patients [are going to progress]." 💬 Enslin: "That's the other unmet need-- how can we provide information to patients in ways that they can understand it, and how do we translate that into a conversation with them?" 💬 Quader: What I normally say [to patients] is that these are all pieces of a puzzle. And we're using all of these small pieces to figure out what I should do for you specifically and not for someone else.

Here's another case study from Dr. Daniel Tseng, in which he ordered #TissueCypher and helped an older patient to be more proactive in preventing esophageal cancer. Check out the case details and see how Dr. Tseng incorporated the insights offered by the patient's TissueCypher score: https://hubs.la/Q02DVpRm0

Castle Biosciences, Inc. supports ASGE in its AI initiative. Knowing how to harness the strengths of AI will be essential in assuring the continued relevance and innovations in GI endoscopy through years to come. TissueCypher - Barrett's Esophagus is the first precision medicine test for prognosticating the risk of nondyplastic BE to develop into high grade dysplasia/esophageal adenocarcinoma. With AI, TissueCypher was built on a robustly validated prognostic platform that has proven itself in 13 peer-reviewed publications, using one of the largest set of Barrett’s esophagus patients from multiple leading institutions in Barrett’s care. We are excited to meet you at the Global GI and AI summit!

Finding and biopsying prevalent disease in Barrett's esophagus can be a challenge. Some studies have shown that 25-33% of Barrett's esophagus associated high-grade dysplasia and cancer can be missed during surveillance endoscopy (Daliwhal et al. Clin Gastroenterol Hepatol. 2021.) While there is no substitute for a high-quality exam, #TissueCypher was studied in prevalent progressors (less than 1 year of endoscopy) and 83% received a intermediate- or high-risk TissueCypher score that could have resulted in upstaging of care. Check out the study: https://hubs.la/Q02B-Vw10 #PeerReviewed #PublishedData

#TissueCypher's first validation study started with 14 candidate biomarkers and numerous morphology and tissue structures. Combining those inputs, the team analyzed 13,538 candidate features. The end result was a properly validated risk prediction model using the 15 most statistically significant features found during the analysis. Fun fact: We call the first validation study "GAPP1," and it was named for the collaborating institutions: (G)eisinger Medical Center, (A)msterdam University Medical Center, University of (P)ittsburgh, University of (P)ennsylvania Check out the study: https://hubs.ly/Q02B-_0C0 #PeerReviewed #PublishedData

Here's another noteworthy insight from our most recent published study: The physicians that adopted #TissueCypher were significantly better at identifying the risk of progression to HGD/EAC — 89.6% for test “adopters” vs. 22.2% for “non-adopters” (p<0.001). Check out the study: https://hubs.la/Q02B5JX10 #BarrettsEsophagus

In this episode of Cases with Castle, Dr. Daniel Tseng describes a non-dysplastic Barrett's esophagus (NDBE) patient *who failed to mention* a key detail in his medical history. After ordering #TissueCypher and receiving a high-risk result, Dr. Tseng dug deeper into the patient history and learned of a prior esophageal cancer diagnosis. Listen to Dr. Tseng's story and check out all his TissueCypher case studies here: https://hubs.la/Q02zJYdp0

Today is World Digestive Health Day! Make your digestive health a priority and visit Get-Checked.org to learn how chronic Heartburn or Reflux Disease can lead to Esophageal Cancer. #WorldDigestiveHealthDay #EsophagealCancer

Our president-elect, Dr. Dan Lister joins Dr. Emmanuel Gorospe, Dr. Farhan Quader, and Sarah Enslin PA to discuss how patients can benefit from TissueCypher. #DDW2024 #AFS

J. Price Corr, MD, is a medical stalwart who helped establish General Surgery as a recognized surgical specialty in #Georgia. Now, he's leading the fight against esophageal cancer by offering #TissueCypher™ for his #GERD patients with #Barrett's esophagus.  TissueCypher™, by Castle Biosciences, Inc., leverages an AI-derived algorithm to identify acid reflux patients with Barrett's esophagus who are likely to progress to esophageal cancer. If you live in Albany, Georgia, and have reflux, look up Dr. Corr and his partners, who proudly work at Albany Surgical Associates. Learn more about the surgical treatment of Acid Reflux.  www.iersurgery.com Institute of Esophageal and Reflux Surgery #Denver, CO HCA Healthcare Sky Ridge Medical Center Mark Valentino - Castle Biosciences - Georgia